Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

ABSTRACT:

Importance

The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics.

Objective

To reveal genomic characteristics from cfDNA associated with clinical outcomes during enzalutamide treatment.

Design, setting, and participants

Plasma samples were obtained from August 4, 2013, to July 31, 2015, at a sing

SUBMITTER: Wyatt AW 

PROVIDER: S-EPMC5097690 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature